Meet:

Age:

INTERNATIONAL ANGELMAN DAY FEB 15

fast

fast ARGENTINA | fast AUSTRALIA | fast CANADA | fast CHILE | fast COLOMBIA | fast FRANCE | fast ITALY | fast UK | fast SPAIN | fast USA | fast LatAm

~500,000 Individuals globally with Angelman Syndrome

23+

AS Therapeutic Programs in the pipeline toward human clinical trials

20+ FAST

Laboratories funded to understand the etiology and identify treatment options for AS



What is Angelman Syndrome?

Angelman syndrome (AS) is a rare neurogenetic disorder that affects approximately one in 15,000 people or approximately 500,000 individuals worldwide. Children and adults with AS typically do not speak verbally. They have balance issues, gross and fine motor impairments and often debilitating seizures. Some individuals never walk. Disrupted sleep cycles also can be a serious challenge to the individual and caretaker(s).

Who is FAST?

Foundation for Angelman Syndrome Therapeutics is run by a driven board of parents of individuals living with Angelman syndrome and professionals dedicated to curing AS through the funding of an aggressive research agenda.

FAST operates as an impartial organization to drive collaboration and sharing across the industry (pharmaceuticals, research institutions and other global organizations) to reach a cure faster. FAST is served by two boards: the board of directors and an independent scientific advisory board. Together, we are working hard to bring practical treatment into current medical practice as quickly as possible.

FAST is committed to finding meaningful and transformative treatments for all individuals living with AS globally, regardless of age or genotype in order to achieve our mission of finding a cure.

Please donate to find a cure for

Add your personal note here.